HCV Fibrosis APRI

HCV Fibrosis APRI: Simple AST-to-platelet ratio index for advanced fibrosis screening in chronic hepatitis C.

Clinical Factors

Assessment Tier

Lower Risk

Score 0

Advanced fibrosis is less likely from the selected profile.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Use during early bedside triage when infection severity or treatment escalation is uncertain.

Support clinician judgement with a structured review of the highest-yield risk factors.

Standardise communication between admitting, ID, ICU, and pharmacy teams.

Section 2

Formula & Logic

Scoring Logic

AST above upper limit of normal (+2)

Platelets <150 ×10⁹/L (+2)

Portal hypertension features (+2)

Low albumin / synthetic dysfunction (+1)

Splenomegaly (+1)

Jaundice or decompensation history (+2)

Section 3

Next Steps

Clinical Actions

Interpret the result together with source control, microbiology, host factors, and trajectory.

Escalate imaging, cultures, or specialist review when the tool lands in a high-risk tier.

Reassess dynamically if the patient deteriorates or new microbiology becomes available.

Section 4

Pearls/Pitfalls

Important Caveat

This tool supports structured infectious-disease decision making but does not replace clinician judgement or local guideline pathways.

Section 5

Evidence Appraisal

Evidence Base

This OpiCalc infectious-disease entry reflects commonly used guideline criteria and bedside risk features used in contemporary clinical practice.

Last Comprehensive Review: 2026

Related Infectious Disease Tools

Dengue NS1 IgM

Dengue Severity WHO

Diabetic Foot Infection

Have feedback about this calculator?Let us know.